Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its holdings in Regeneron Pharmaceuticals by 105.2%, owning 1,917 shares valued at approximately $1.2 million as of its latest SEC filing.
• Analysts have mixed views on Regeneron, with a consensus rating of "Moderate Buy" and a current price target of $838.00, with several firms adjusting their price objectives recently.
• Regeneron Pharmaceuticals reported $12.89 earnings per share, beating estimates significantly, and also announced a quarterly dividend of $0.88 per share to be paid in September.

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 105.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,917 shares of the biopharmaceutical company's stock after buying an additional 983 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $1,216,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Curat Global LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ:REGN traded down $2.13 during midday trading on Tuesday, reaching $571.78. The company's stock had a trading volume of 854,560 shares, compared to its average volume of 1,109,174. The firm has a market cap of $60.60 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The business has a 50 day moving average price of $545.33 and a 200 day moving average price of $593.59.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the business earned $11.56 earnings per share. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.